Genfit SA (GNFT.PA) stock: key figures, P/E, revenue and dividend
Health Care · France · ISIN FR0004163111
Genfit SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 70.00 m EUR | 65.43 m EUR |
| Gross profit | 68.00 m EUR | 14.55 m EUR |
| Operating income | – | -58.92 m EUR |
| EBIT | 3.00 m EUR | – |
| Net income | 1.51 m EUR | -85.97 m EUR |
| Diluted EPS – continuing operations | 0.03 EUR | -1.72 EUR |
Full history since 2003, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Genfit SA
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcinoma; and G1090N/NTZ, which is in Phase 1 clinical trial for the treatment of acute-on-chronic liver failure continuum. In addition, the company is involved in the development of drugs in preclinical stage, including SRT-015, CLM-022, and EViv for the treatment of acute-on-chronic liver failure continuum; VS-02-HE for the treatment of hepatic encephalopathy; and VS-01-HAC (UCD/OA) for the treatment of hyperammonemic crises, urea cycle disorder, and organic acidemias. It has strategic partnerships with Ipsen for the development and commercialization of elafibranor; and Labcorp for the development and commercialization of NASHnext, a blood-based molecular diagnostic test, as well as TS-01, a diagnostic tool for blood ammonia levels. The company was incorporated in 1999 and is headquartered in Loos, France.
More stocks
- ITM Power PLC (ITM.L)
- Hangzhou AGS MedTech Co. Ltd. A (688581.SS)
- Shenzhen Longtech Smart Control Co. Ltd. (300916.SZ)
- Dacotah Banks Inc (DBIN)
- SK Chemicals Co Ltd (285130.KS)
- Spearhead Integrated Marketing (300071.SZ)
- Mensch und Maschine Software (MUM.DE)
- Doman Building Materials Group Ltd (DBM.TO)
- GlobalData PLC (DATA.L)
- M Grass Ecology and Environment Group Co Ltd (300355.SZ)
- Nankang Rubber Tire Corp Ltd (2101.TW)
- Suzhou Etron Technologies Co Ltd (603380.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.